Bevacizumab and PEGylated Liposomal Doxorubicin in the Treatment of Relapsed Osteosarcoma

Asleh M, Abu Quider A, Ben-Harosh M, Fruchtman Y, Beck G and Kapelushnik J*

Department of Pediatric Hematology-Oncology, Soroka University Medical Center, Israel

^*Correspondance to: Joseph Kapelushnik 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: Treatment of relapsed osteosarcoma is challenging and prognosis is dismal. Many second-line treatments have been tried with no breakthrough in response rate. PEGylated liposomal doxorubicin and bevacizumab have been shown to be effective in treating sarcomas, but they were never given in combination for osteosarcoma patients. Methods: A restrospective case review of 3 patients with relapsed or refractory osteosarcoma who were treated with bevacizumab (5 to 15 mg/kg every 2 to 8 weeks) and PEGylated liposomal doxorubicin (50 mg/m2 every 3 to 4 weeks) was undertaken. Results: Two of three patients received a complete remission on this treatment with event-free survival of 7.6 years and 4.3 years on their last follow-up. Toxicity profile was acceptable for bevacizumab with 1of 3 patients experiencing mild proteinuria which resolved with dose reduction. 1 of 3 patients suffered a severe side effect of PEGylated liposomal doxorubicin (palmoplantar erythrodysesthesia) that forced us to withhold the treatment. Conclusion: A combination of bevacizumab and PEGylated liposomal doxorubicin could be an efficient treatment option for patients with relapsed osteosarcoma suffering minimal disease.

Keywords:

Cite the Article:

Asleh M, Abu Quider A, Ben-Harosh M, Fruchtman Y, Beck G, Kapelushnik J. Bevacizumab and PEGylated Liposomal Doxorubicin in the Treatment of Relapsed Osteosarcoma. Clin Oncol. 2019; 4: 1646 .